Annuncio pubblicitario
Italia markets closed
  • FTSE MIB

    33.629,21
    -107,19 (-0,32%)
     
  • Dow Jones

    38.675,68
    +450,02 (+1,18%)
     
  • Nasdaq

    16.156,33
    +315,37 (+1,99%)
     
  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     
  • Petrolio

    77,99
    -0,96 (-1,22%)
     
  • Bitcoin EUR

    58.622,06
    +388,68 (+0,67%)
     
  • CMC Crypto 200

    1.313,01
    +36,03 (+2,82%)
     
  • Oro

    2.310,10
    +0,50 (+0,02%)
     
  • EUR/USD

    1,0765
    +0,0038 (+0,36%)
     
  • S&P 500

    5.127,79
    +63,59 (+1,26%)
     
  • HANG SENG

    18.475,92
    +268,79 (+1,48%)
     
  • Euro Stoxx 50

    4.921,48
    +30,87 (+0,63%)
     
  • EUR/GBP

    0,8577
    +0,0023 (+0,27%)
     
  • EUR/CHF

    0,9735
    -0,0024 (-0,25%)
     
  • EUR/CAD

    1,4726
    +0,0064 (+0,44%)
     

154,112 Orion Corporation A shares converted into B shares

Orion Oyj
Orion Oyj

ORION CORPORATION
STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
25 JANUARY 2023 at 9.00 EET

154,112 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 154,112 A shares have been converted into 154,112 B shares. The conversion has been entered into the Trade Register on 25 January 2023.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,032,382 A shares and 107,101,896 B shares. The number of votes of the company's shares is after the conversion 787,749,536.

ANNUNCIO PUBBLICITARIO

Orion Corporation

Jari Karlson

CFO

   

Olli Huotari

SVP, Corporate Functions

 


Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.